For the open-label extension, baseline data were acquired at the time of the initial infusion of tocilizumab for individuals who made the transition from placebo to tocilizumab. The efficacy and safety populations included all patients who underwent randomization and received at least one dosage of study medication. Efficacy results are presented up to week 52 of treatment with tocilizumab. Basic safety data include full-publicity data for each patient. The exposures of individual sufferers to tocilizumab varied, with respect to the period from the first dosage of tocilizumab to the date of data cutoff or withdrawal .Kaiser Family Foundation. Copyright 2007 Advisory Board Kaiser and Company Family members Foundation. All rights reserved.. Narrow retinal arteries associated with increased risk for glaucoma Abnormally Results of 10-year research published in the journal of the American Academy of Ophthalmology suggest a fresh detection tool A fresh study finds that one changes in blood vessels in the eye's retina is definitely an early warning a person reaches increased risk for glaucoma, an eyes disease that robs people of their peripheral eyesight slowly. Using diagnostic photos and various other data from the Australian Blue Mountains Vision Study, the researchers showed that sufferers who acquired abnormally narrow retinal arteries when the study began were also those who were most likely to have glaucoma at its 10-12 months end point.